{
  "docId": "019de073-8568-725b-9a17-a64262808fc8",
  "docSlug": "d872feff7a8967ecac479e446ba0e3da",
  "documentTitle": "Context Therapeutics | Investor Presentation Deck | 25 slides",
  "authorId": "context-therapeutics",
  "authorName": "Context Therapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-09-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 3,
  "pageCount": 25,
  "prevPage": 2,
  "nextPage": 4,
  "slideType": "executive_summary",
  "function": "summarize",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": "The slide uses a structured table-like layout to categorize key business and clinical updates.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-8568-725b-9a17-a64262808fc8/3",
  "deckHref": "/decks/019de073-8568-725b-9a17-a64262808fc8",
  "deckJsonHref": "/decks/019de073-8568-725b-9a17-a64262808fc8.json",
  "deckAnchorHref": "/decks/019de073-8568-725b-9a17-a64262808fc8#slide-3",
  "components": [
    {
      "bbox": {
        "h": 0.18,
        "w": 0.9,
        "x": 0.048,
        "y": 0.55
      },
      "kind": "list",
      "text": "CLDN6 x CD3 bispecific antibody: Uniquely expressed in certain cancers; developing selective antibody; candidate selection Q4 2022, IND Q1 2024",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "40a1d87d-be2e-4cb9-9eb7-80f4d0884554",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.9,
        "x": 0.048,
        "y": 0.8
      },
      "kind": "list",
      "text": "Cash Guidance: Expected cash runway into Q1 2024",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a4e2b8c3-9ea8-45ab-919b-72d2b89b1ab1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.9,
        "x": 0.048,
        "y": 0.17
      },
      "kind": "list",
      "text": "Focus on Women's Oncology: Unmet clinical need in breast, ovarian, and endometrial cancers",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bf0aa747-8257-425f-9ff2-742bde092a23",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.18,
        "w": 0.9,
        "x": 0.048,
        "y": 0.3
      },
      "kind": "list",
      "text": "ONA-XR oral PR antagonist: Novel, potentially first-in-class PR antagonist; Q4 2022 ELONA trial initiation; Q4 2022 preliminary IST data",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ea0c89f5-3312-46ec-b7e6-49e011d28b4b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.035,
        "w": 0.37,
        "x": 0.048,
        "y": 0.075
      },
      "kind": "title",
      "text": "Context Therapeutics Overview",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0de2da34-00ab-4881-a6b1-8098689a48bf",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "a3bff797-e756-4ae1-a017-8c82f5e5955e",
      "evidence": "list/bullet: CLDN6 x CD3 bispecific antibody: Uniquely expressed in certain cancers; developing selective antibody; candidate selection Q4 2022, IND Q1 2024",
      "confidence": 0.8
    },
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "41326e5e-b72e-468f-994f-297dcaa36456",
      "evidence": "list/bullet: ONA-XR oral PR antagonist: Novel, potentially first-in-class PR antagonist; Q4 2022 ELONA trial initiation; Q4 2022 preliminary IST data",
      "confidence": 0.8
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}